A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

Trial Details

NCT ID

NCT07748208

Phase

PHASE2

Sponsor

Hoffmann-La Roche

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

• Inavolisib
• Fulvestrant
• Palbociclib

Locations (sample)

• Washington D.C., District of Columbia, United States|38.89511,-77.03637
• Atlanta, Georgia, United States|33.749,-84.38798
• Atlanta, Georgia, United States|33.749,-84.38798
• Atlanta, Georgia, United States|33.749,-84.38798
• Grand Island, Nebraska, United States|40.92501,-98.34201

Key Eligibility Criteria

• Type 2 diabetes with laboratory fasting blood glucose \< 185 milligrams per deciliter (mg/dL) and HbA1c \<= 8% on any stable anti-hyperglycemic reg…
• Eligible for triplet of inavolisib, fulvestrant and palbociclib: no prior systemic therapy for locally advanced unresectable or metastatic disease
• Confirmed diagnosis of HR+/HER2- breast cancer
• Confirmation of biomarker eligibility (detection of specified mutation(s) of PIK3CA via specified test)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.